A Clinic Says It Uses MSCs What Does That Actually Tell Us

A clinic website says it offers an MSC treatment. The page may mention “regenerative cells,” “exosomes,” “Wharton’s jelly,” “amniotic tissue,” “adipose-derived cells,” or “bone marrow concentrate.” The language sounds scientific, but after a few minutes of reading, a basic question can become harder to answer rather than easier.

What is actually being used?

That confusion is the point of this edition of Stem Cell Chronicles “What the Cell?” The term MSC often gets treated like a badge of legitimacy. It can suggest a living stem cell product with a clear mechanism, a known source, and evidence for a specific use. In reality, “MSC” is a starting clue, not a conclusion.

This article does not accuse any clinic of wrongdoing. It offers a practical way to investigate a claim. If a U.S. clinic says it uses MSCs, the next step is to ask better questions.

A vague cell therapy claim should lead to questions, not assumptions.

MSC can mean more than one thing

MSC usually stands for mesenchymal stem cell or mesenchymal stromal cell. Those terms are often used loosely in public-facing material, and they are not always interchangeable in a scientific sense.

In research settings, MSCs are commonly described by features such as how they grow in culture, which surface markers they express, and how they behave under certain lab conditions. That does not mean every product advertised with MSC language contains living MSCs, contains many MSCs, or contains cells that can do what the marketing suggests.

A consumer-facing claim may refer to several different things:

• A product that contains living cells

• A tissue product that may have once contained cells

• A processed birth tissue product, such as amniotic membrane or umbilical cord-derived material

• Bone marrow concentrate collected from the same patient

• Adipose-derived material collected from fat tissue

• Conditioned media, extracellular vesicles, or exosome-related products

• A general “regenerative” service using MSC-related language

  
  

Those are not minor differences. They can affect safety, legality, evidence, and biological plausibility.

A useful first move is to separate the word from the product. “MSC” tells you what topic the clinic wants to signal. It does not, by itself, tell you what is in the syringe.

Ask what the product actually is

A clear claim should identify the product in concrete terms. If the description stays abstract, keep asking.

Good questions include:

• Is this a cell product, tissue product, biologic, drug, device, or procedure?

• What is the product’s proper name?

• Is it made on-site, purchased from a supplier, or prepared by a third-party lab?

• Is it fresh, frozen, thawed, cultured, concentrated, filtered, enzymatically processed, or combined with anything else?

• Is the treatment autologous, meaning from the same patient, or allogeneic, meaning from a donor?

  
  

The answers matter because “MSC treatment” can cover very different scenarios.

For example, a same-day bone marrow concentrate procedure is not the same thing as an expanded donor-derived cell product grown in culture. A vial of cryopreserved birth tissue material is not the same thing as freshly isolated living cells from a patient’s own tissue. A product described as “rich in signaling molecules” may not be a viable cell product at all.

Here is a simple way to sort the early questions.

Question	Why it matters
What is the product called?	A specific name makes it easier to evaluate claims and documentation.
Who made it?	Manufacturing standards, quality testing, and oversight depend on the source.
Is it from the patient or a donor?	Autologous and donor-derived products raise different questions.
Is it living cells or tissue material?	Viability affects what “MSC” can reasonably mean.
What is being treated?	Evidence is use-specific, not general.

If the answer is “our product uses MSC technology” or “it contains regenerative factors,” that may be too vague to evaluate. Ask for the plain-language version.

Ask where the cells come from

The source of the material is one of the most important facts.

Common sources discussed in MSC-related treatment include bone marrow, fat tissue, umbilical cord tissue, Wharton’s jelly, amniotic tissue, and placenta-derived materials. Each source raises its own questions.

Bone marrow

Bone marrow contains a mix of cells, including a small population that may meet MSC-related criteria in lab settings. A same-day bone marrow concentrate procedure usually produces a mixed cell concentrate, not a purified MSC product.

Useful questions include:

• Was the sample tested for cell count or viability?

• Is the clinic claiming the product contains MSCs specifically, or a broader mix of marrow-derived cells?

• Was the material expanded in culture, or used the same day?

  
  

Culturing cells can change the regulatory and safety picture. Same-day concentration and culture expansion are not the same process.

Adipose tissue

Fat-derived products can also contain cell populations of interest. But adipose processing varies widely. Some methods use mechanical processing. Others use enzymes. Those details matter because they can affect the product’s classification, composition, and regulatory pathway.

Ask what tissue is collected, how it is processed, and whether the clinic claims that the resulting cells are intended to perform the same basic function in the recipient as they did in the donor tissue.

Birth tissue products

Umbilical cord, Wharton’s jelly, amniotic, and placental products are often marketed with MSC-related language. This area can be especially confusing because a product may be derived from tissue associated with MSC research without containing viable MSCs in a meaningful amount.

A birth tissue product may be decellularized, frozen, processed, sterilized, or otherwise treated in ways that affect living cells. Some products may contain no viable MSCs, even if the source tissue is discussed in MSC terms.

That does not automatically tell you whether a product is useful or not. It means the label is not enough.

The source of the material changes the questions that need to be asked.

Ask whether viable MSCs are actually present

This is the question marketing often skips.

A product could be “derived from” a tissue that has MSCs in the research literature. That does not prove the final product contains living MSCs. It also does not prove that the cells are present in a clinically meaningful number.

To evaluate the claim, ask for evidence tied to the final product, not just the source tissue.

Questions to ask include:

• Has the final product been tested for viable nucleated cells?

• Has it been tested specifically for MSC-like cells?

• What markers or assays were used?

• Are the results lot-specific, patient-specific, or based on general supplier materials?

• Does the clinic have a certificate of analysis?

• Is viability measured after thawing, if the product is frozen?

  
  

A certificate of analysis may include items such as sterility testing, endotoxin testing, cell count, viability, and other quality checks. It may not answer every question, but it can show whether basic product testing exists.

Be careful with phrases like “contains millions of stem cells.” That claim should lead to follow-up questions. Millions of what cells? Counted how? Before or after processing? Before or after freezing and thawing? Were they characterized as MSCs, or counted as total nucleated cells?

The phrase viable MSCs has a specific implication. It suggests living cells with MSC-like properties. If the product is acellular, mostly nonviable, or not tested for MSC identity, the claim needs clarification.

Ask how the product is processed

Processing is not a technical footnote. It can change the product.

Cells and tissues may be:

• Washed

• Filtered

• Centrifuged

• Minced

• Digested with enzymes

• Cryopreserved

• Thawed

• Expanded in culture

• Combined with other substances

• Sterilized or treated to reduce contamination risk

  
  

Each step can affect cell survival, composition, contamination risk, potency, and regulatory status.

For example, expanding cells in culture may increase cell numbers, but it also introduces manufacturing questions. How many passages were used? What media was used? Were animal-derived components involved? What sterility tests were done? Were genetic stability or potency assessed?

For frozen products, thawing matters. Cells can lose viability after freeze-thaw cycles. A product that looks promising in a brochure may behave differently after shipping, storage, and preparation at the clinic.

Processing also affects whether the product fits within certain FDA categories. A procedure described as “simple” in marketing may involve steps that regulators consider significant.

Processing steps can change what a cell or tissue product is.

Ask which regulatory pathway applies

In the United States, cell and tissue products may fall under different FDA frameworks. The details can get technical, but a few concepts help.

Some human cells, tissues, and cellular and tissue-based products, often called HCT/Ps, may be regulated under section 361 of the Public Health Service Act if they meet specific criteria. These include concepts such as minimal manipulation and homologous use. If a product does not meet the criteria, it may be regulated as a drug, biologic, or device under section 351, which usually requires an approved biologics license application or an investigational new drug pathway for clinical studies.

The key terms are worth translating.

Minimal manipulation asks whether processing changes relevant characteristics of the tissue or cells.

Homologous use asks whether the product is used to perform the same basic function in the recipient as it performed in the donor.

Autologous use refers to use in the same person from whom the cells or tissue came.

Same surgical procedure exception may apply in limited situations when tissue is removed and implanted back into the same patient during the same surgical procedure, with only certain handling steps.

These categories are fact-specific. A clinic’s website may not provide enough information to tell which pathway applies. That is why asking directly matters.

Good questions include:

• Is this product FDA-approved for this specific use?

• If not approved, is it being used under an investigational new drug application?

• Is it being offered as a 361 HCT/P?

• Is the clinic relying on the same surgical procedure exception?

• What is the stated homologous use?

• Has the FDA issued any public guidance relevant to this type of product?

  
  

A careful clinic should be able to explain its regulatory view in plain language. That does not mean every consumer can verify the whole analysis alone. It does mean vague phrases like “FDA registered,” “FDA compliant,” or “made in an FDA-registered lab” should not be treated as the same thing as FDA approval for a specific treatment.

A registered facility is not the same as an approved product. A listed product is not the same as a product proven safe and effective for a disease. Those distinctions matter.

Ask what evidence supports the intended use

Evidence for one use does not automatically support another.

An MSC-related product studied for one condition, by one route of administration, at one dose, in one patient population, does not prove it works for a different condition. A knee injection, an intravenous infusion, a spinal injection, and a topical wound application are different uses with different risk profiles.

When evaluating evidence, ask:

• What condition is being treated?

• What outcome is the clinic claiming?

• Is the evidence from human clinical trials?

• Were the trials randomized or controlled?

• Was the specific product studied?

• Was the same cell source used?

• Was the same dose and route used?

• Were benefits measured against placebo, standard care, or natural recovery?

• What adverse events were reported?

  
  

Patient testimonials can describe personal experiences, but they cannot prove that a treatment caused improvement. Many conditions fluctuate. Pain can improve for reasons unrelated to a cell product. Placebo effects can be real and powerful. Rehabilitation, rest, injections, medication changes, and time may all influence outcomes.

Laboratory studies and animal studies can help researchers build hypotheses. They do not prove that a clinic treatment works in people. Early human studies can be useful, but small uncontrolled studies are not the same as strong clinical evidence.

The best question is not “Are MSCs promising?” The better question is, what evidence supports this exact product for this exact use in patients like me?

Evidence should match the product, dose, route, and condition being treated.

A practical script for calling a clinic

The goal is not to sound confrontational. The goal is to get clear answers.

Try questions like these:

1. What is the exact product or procedure you use?

2. Is it from my own body or from a donor?

3. What tissue is it derived from?

4. Does the final product contain living MSCs?

5. How do you test cell count, viability, sterility, and identity?

6. Is the product FDA-approved for the condition being treated?

7. If not, what regulatory pathway are you using?

8. What published human evidence supports this product for this condition?

9. What risks are known for this route of administration?

10. Can I review the consent form and product information before paying?

Clear answers do not guarantee that a treatment is appropriate. Unclear answers do tell you that more investigation is needed.

Also watch for language that skips specifics. Phrases such as “activates healing,” “regenerates tissue,” or “uses your body’s natural repair system” may sound appealing, but they need evidence behind them. Ask what was measured, in whom, and compared with what.

The takeaway is to investigate the claim, not the label

“MSC” is not a verdict. It is a prompt for better questions.

A clinic may use MSC-related language for a same-day autologous procedure, a donor-derived tissue product, a cultured cell product, or something that contains few or no viable cells. Those options differ in source, processing, regulation, risk, and evidence.

The most useful approach is steady and practical:

• Identify the product.

• Trace the source.

• Confirm whether viable MSCs are present.

• Understand the processing.

• Ask which FDA pathway applies.

• Match the evidence to the intended use.

  
  

This article is for general information and is not medical or legal advice. Anyone considering a cell or tissue-based intervention should discuss it with a qualified health professional who is not financially tied to the treatment.

Marketing language can open the door, but it should not close the investigation. The phrase “uses MSCs” tells you where to begin. It does not tell you enough to decide.